While patients suffering from IDHwt glioblastoma receiving standard treatment have an average overall survival of 15–18 months [6,7], average overall survival can be up to 14.7 years in patients with oligodendroglioma in the presence of an IDH mutation and combined loss of heterozygosity (LOH) 1p/19q under sufficient treatment [8,9]. Here, IDH2 is linked to oligodendroglioma.